15159-40-7

Basic information

• Product Name: 4-Morpholinecarbonyl chloride
• Synonyms: 4-Morpholinecarbonyl;4-Chlorocarbonylmorpholine Morpholinocarbonyl Chloride;MORPHOLINE-4-CARBONYL CHLORIDE;MORPHOLIN-4-YLCARBONYL CHLORIDE;MORPHOLINOCARBONYL CHLORIDE;4-MORPHOLINE CARBONIC ACID CHLORIDE;4-MORPHOLINECARBONYL CHLORIDE;4-MORPHOLINYLCARBONYL CHLORIDE
• CAS NO: 15159-40-7
• Molecular Formula: C₅H₈ClNO₂
• Molecular Weight: 149.58
• EINECS: 239-213-0
• Product Categories: Building Blocks;Chemical Synthesis;Heterocyclic Building Blocks;Morpholines/Thiomorpholines;ACIDHALIDE;Phosgene Derivatives;Building Blocks;Heterocyclic Building Blocks;Morpholines
• Mol File: 15159-40-7.mol
• Article Data: 37

Chemical Properties

• Boiling Point: 137-138 °C33 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.282 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0418mmHg at 25°C
• Refractive Index: n20/D 1.498(lit.)
• Storage Temp.: Store below +30°C.
• PKA: -2.16±0.20(Predicted)
• BRN: 116257
• CAS DataBase Reference: 4-Morpholinecarbonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Morpholinecarbonyl chloride(15159-40-7)
• EPA Substance Registry System: 4-Morpholinecarbonyl chloride(15159-40-7)

Safety Data

• Hazard Codes: Xn
• Statements: 14-36/38-40
• Safety Statements: 26-30-36-38
• RIDADR: UN 3265 8/PG 2
• WGK Germany: 3
• F: 10-21
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 15159-40-7(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 15159-40-7 differently. You can refer to the following data:
1. Photographic intermediate
2. 4-Morpholinecarbonyl chloride may be used in the preparation of a versatile fluorogenic label for biomolecular imaging. It may be used in the synthesis of:morpholine-4-carboxylic acid [4-(2,4-dimethylphenyl)thiazol-2-yl]amidemorpholine-4-carboxylic acid [4-(2,4,6-trimethylphenyl)thiazol-2-yl]amide2-isopropyl-6-methylpyrimidin-4-yl morpholine-4-carboxylate

General Description

4-Morpholinecarbonyl chloride is a photographic intermediate. Rates of solvolysis of 4-morpholinecarbonyl chloride with N-alkyl group in aqueous binary solvents of acetone, ethanol, methanol, methanol-d, 2,2,2-trifluoroethanol, pure water and D2O has been determined. Preparation of 4-morpholinecarbonyl chloride has been reported.

InChI:InChI=1/C5H8ClNO2/c6-5(8)7-1-3-9-4-2-7/h1-4H2

Upstream product

• 110-91-8 morpholine 
• 75-44-5 phosgene 
• 6976-49-4 morpholine-4-carboxylic acid ethyl ester 
• 50881-96-4 morpholine-4-carboxylic acid 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 2757-23-5 chloro(chlorosulfanyl)methanone 
• 140-89-6 potassium ethyl xanthogenate 
• 1199-46-8 2-amino-4-tert-butylphenol 
• 301840-94-8 PdCl(CONCH₂CH₂OCH₂CH₂)(1,10-phenanthroline) 
• 7782-50-5 chlorine 
• 301840-96-0 Pd(CONCH₂CH₂OCH₂CH₂)2(2,2'-dipyridine) 
• 301840-93-7 PdCl(CONCH₂CH₂OCH₂CH₂)(2,2'-dipyridine) 
• 128-09-6 N-chloro-succinimide 
• 7553-56-2 iodine 

Downstream Products

• 688745-55-3 1-(3-bromo-2-hydroxy-5-methylphenyl)-3-morpholin-4-yl-3-oxopropan-1-one 

Relevant articles and documents

-

-

Cannabidiol carbamate compound, pharmaceutical preparation, preparation method and application

The invention relates to a cannabidiol carbamate compound, a medicinal preparation, a preparation method and application, and belongs to the field of compounds for treating and preventing diseases related to aging, Alzheimer's disease and Parkinson's disease. The compound has a structure shown as a formula I or a pharmaceutically acceptable salt of the structure shown as the formula I. The compound has good butyrylcholine esterase resisting activity, shows good application prospect in treatment of Alzheimer's disease, and shows good application potential.

LOX ENZYME INHIBITING METHODS AND COMPOSITIONS

This invention relates to compounds, pharmaceutical compositions and their use for treating fibrotic disorders, proliferative disorders, cardiovascular diseases, acute and chronic inflammatory disorders, primary and metastatic cancer, pulmonary conditions, ocular diseases, or neurological and neuropsychiatric conditions. One particular aspect of the inventions relates to inhibitors of the family of lysyl oxidase enzymes and their use as therapeutics for fibrotic disorders.